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Antigenic variants of foot-and-mouth disease virus (FMDV) were generated and frequently became dominant
in clonal populations of FMDV (clone C-S8cl) grown in the absence of anti-FMDV antibodies. We have now
passaged eight samples of the same FMDV clone in the presence of a limited amount of neutralizing polyclonal
antibodies directed to the major antigenic site A of capsid protein VP1. Complex populations of variants
showing increased resistance to polyclonal sera and to site A-specific monoclonal antibodies were selected. Some
populations exhibited marked decreases in viral fitness. Multiple amino acid replacements within site A-and
also elsewhere in VP1-accumulated upon passage of the virus in either the absence or the presence of
neutralizing antibodies. However, antigenically critical replacements at one position in site A occurred
repeatedly in FMDV passaged under antibody selection, but they were never observed in many passages
carried out either in the absence of antiviral antibodies or in the presence of an irrelevant antiviral serum.
Thus, even though antigenic variation of FMDV can occur in the absence or presence of immune selection,
critical replacements which lead to important changes in antigenic specificity were observed only as a result of
selection by neutralizing antibodies.
RNA virus populations replicate as complex distributions
of nonidentical but closely related genomes termed viral
quasispecies (13-19, 21, 26, 27). Extreme genetic heteroge-
neity is the result of high mutation rates-estimated on
average as 10- to 10-' substitutions per nucleotide site per
round of copying-during RNA genome replication and
retrotranscription (2, 15, 16, 18, 19, 21, 26, 27). Thus, at any
one time in a defined environment RNA genomes may
possess a defined consensus sequence, but the population
consists of a swarm of slightly different individual genomes
(14-19, 39, 45, 47). Three mechanisms have been distin-
guished as acting to modify viral quasispecies and to pro-
mote virus evolution (reviewed in reference 16): (i) a modu-
lating action of negative selection by which any new variant
is rated in competition with all other variants present in the
quasispecies (as a result of such rating, low-fitness variants
are kept at low levels in the population); (ii) positive Dar-
winian selection driving a previously neutral or unfit variant
to dominance in response to an environmental change (es-
cape mutants selected in the presence of neutralizing anti-
bodies are an example of positive Darwinian selection); and
(iii) random sampling events in which one genome from a
population may be amplified and become dominant irrespec-
tive of its competitive fitness (51). The relative contribution
of positive selection versus random drift of neutral or nearly
neutral alleles in long-term evolution is still subject to
considerable debate both for cellular organisms and for RNA
viruses (13, 22, 29, 49).
Recent evidence suggests that antigenic variation of vi-
ruses may occur upon virus replication in the absence of any
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detectable immune selection (3-5, 11, 12, 14, 28, 31, 43, 44,
52). This observation has been explained by two possible
models (13, 14). First, residues at antigenic sites may be
involved in viral functions unrelated to the evoking of an
immune response. Such residues may be replaced as a result
of selective forces unconnected to immune pressure, but the
replacements may fortuitously contribute to antigenic vari-
ation (4, 28). The second model-termed the random change
model (14)-suggests that fluctuations in the genomic distri-
butions of a quasispecies-triggered by any selective force
other than immune selection, or by random sampling
events-may mediate the hitchhiking of mutations occurring
at those genomic sites where mutations are more tolerated.
This model proposes that antigenic sites will, on average,
tolerate more replacements than other capsid residues be-
cause antigenic sites are located on exposed surface loops
relatively free of structural constraints (12, 14, 43). Thus,
antigenic variation may result either from positive immune
selection or from hitchhiking of substitutions at antigenic
sites belonging to genomes selected by other traits or ampli-
fied by chance events.
Antigenic variants of foot-and-mouth disease virus
(FMDV) may become dominant upon passage of the virus
with antiviral polyclonal sera (7, 42) but also in the absence
of any immune selection (3, 11, 12, 25, 31). The capsid of this
picomavirus includes a disordered, protruding loop (the G-H
loop spanning positions 129 to 165 of VP1) (1, 30). This loop
is highly variable in sequence, and in FMDV of serotype C,
it contains multiple, continuous epitopes which constitute
antigenic site A (36, 37, 48). Serial passage of FMDV C-S8cl
in the absence of anti-FMDV antibodies resulted in the
frequent fixation of amino acid replacements within anti-
genic site A which led to altered reactivity with monoclonal
antibodies (MAbs) (11, 12, 25, 31). Now we report that
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propagation of FMDV C-S8cl in the presence of a limited
amount of neutralizing polyclonal antibodies-directed spe-
cifically against a synthetic peptide representing residues 133
to 156 of the G-H loop of VP1-resulted in a repertoire of
amino acid substitutions which is not identical to the reper-
toire fixed in the absence of antibody selection. In particular,
we show that substitution of an antigenically critical amino
acid-which results in the loss of many epitopes within site
A-occurred only as a result of selection by antibodies. In
addition to implications for our understanding of antigenic
diversification of variable RNA viruses, the results show
that the detailed molecular modifications of a viral protein as
a result of Darwinian selection need not be identical to
modifications in the absence of positive selection even
though similarities in the resulting phenotypic modification
may be observed.
MATERIALS AND METHODS
Cells and viruses. BHK-21 cells were grown in Dulbecco's
modification of Eagle's medium with 5% heat-inactivated (30
min, 56°C) fetal calf serum. FMDV C-S8cl is a three-times
plaque-purified derivative of the natural isolate FMDV C-Sta
Pau Sp/70, which was described previously (45). Infections
of BHK-21 cell monolayers with FMDV in liquid culture,
plaque assays, and isolation of FMDV from single plaques
were carried out as previously described (45).
Peptide synthesis. Peptide A24 representing VP1 residues
133 to 156 of FMDV C-S8cl with an additional C-terminal
cysteine residue [sequencelJFTYTASARGDLAHLlTlTHA
RHLP(C) (single-letter amino acid code)] was synthesized,
purified, and coupled to keyhole limpet hemocyanin as
previously described (6). Purity was >95% as judged by
reversed-phase high-performance liquid chromatography,
and identity was confirmed by amino acid analysis and
electrospray mass spectroscopy.
Immunization of guinea pigs and neutralization assays.
Four Dunkin Hartley guinea pigs were immunized with 260
,ug of peptide A24 in complete Freund's adjuvant. Two
booster immunizations were given with intervals of 28 days,
by administration of the same amount of peptide in incom-
plete Freund's adjuvant. Animals were bled before the first
inoculation and 2 weeks after each administration of antigen;
clarified sera were kept at -20°C until use. Sera raised
against peptide A24 in four guinea pigs have been termed a,
b, c, and d. In addition, a serum from a guinea pig inoculated
with herpes simplex virus type 1 (serum h; kindly supplied
by L. Capa and L. Carrasco) was used as control. Serum
neutralization titers were determined by plaque reduction
with serial dilutions of polyclonal serum or MAb, as previ-
ously described (38). The neutralizing MAbs directed to
antigenic site A of FMDV type C have been previously
described (34, 36).
Serial passage of FMDV C-S8cl. Serial infections of
BHK-21 cell monolayers (2 x 106 to 4 x 10' cells) with
FMDV C-S8cl in the absence of anti-FMDV antibodies were
carried out at a multiplicity of infection of either 0.01 to 0.02
PFU per cell or 2 to 4 PFU per cell, for a minimum of 20 and
a maximum of 100 passages, as described previously (12,
45). To treat and passage FMDV C-S8cl with antipeptide
antibodies (serum a, b, c, or d), about 106 PFU was mixed
with a dilution of serum that caused a reduction of virus titer
of either about 102.7 (sera a and b) or about 101 (sera c and d).
Then, the virus was adsorbed onto BHK-21 cell monolayers
for 1 h at 37°C, and the monolayers were extensively washed
with Dulbecco's modification of Eagle's medium. The infec-
tion in liquid culture was allowed to proceed in the presence
of a 10-fold further dilution of each respective serum until
cytopathology was complete (24 to 48 h after infection). The
progeny of each infection were subjected to identical treat-
ment and used to infect a fresh BHK-21 cell monolayer. The
concentration of sera b, c, d, and h was increased 10-fold
after the 10th passage; serum h was used at the same dilution
as serum b. Duplicate series of infections were carried out
for each serum; they have been termed al, a2, . . hl, and
h2. Viral populations are also designated according to the
serum in which they were passaged except that the corre-
sponding capital letter is used: Alp2O is FMDV C-S8cl
treated with serum a and passaged 20 times under selection
by serum a. In some cases, a virus was further passaged in
the absence of anti-FMDV antibodies: Alp2O,plO-1 is
FMDV C-S8cl treated with serum a, passaged 20 times with
serum a, and then passaged 10 times without anti-FMDV
serum; for the latter series, the last number (1 or 2) refers to
the duplicate series of passages. A scheme of the passage
histories of the FMDV C-S8cl derivatives analyzed in the
present study is depicted in Fig. 1.
Nucleotide sequencing. FMDV RNA was sequenced by the
femtomole method (Promega). First, the RNA encoding VP1
was copied into cDNA with primer 5'GAAGGGCCCAGGG
TIGGACT3' (complementary to the RNA region encoding
the 2A-2B junction). Then, the cDNA was amplified by
polymerase chain reaction with the same primer and primer
5'CCTGTGGACGCTAGACA3' (corresponding to residues
1546 to 1562 of the FMDV C-S8cl capsid-encoding region;
numbering is as in reference 11). For sequencing, one of the
above two primers or 5'GCACGC1TCATGCGCAC3' (com-
plementary to residues 2086 to 2102 [11]) or 5'GGGGCAC
CGTTGGGCACC3' (complementary to residues 1829 to
1847) was used with dideoxynucleotide chain terminators as
directed by the supplier (Promega). Double or multiple
bands were observed in a few sites of some variant popula-
tions; they are indicated in the corresponding figures when
they could be eliminated neither by using an alternative
oligonucleotide primer for sequencing the complementary
strand nor by employing formamide-polyacrylamide se-
quencing gels. In some cases, populations showing multiple
bands at one site were subjected to clonal analysis, and in all
cases, the analysis revealed sequence heterogeneity at the
corresponding site among the clones tested.
RESULTS
Fitness decrease and antigenic variation in response to
neutralizing antibodies directed to a synthetic peptide repre-
senting antigenic site A of FMDV. Serial passages of FMDV
C-S8cl were carried out in the presence of anti-peptide A24
serum (eight series) or in the presence of an irrelevant
antiviral serum (two series). In addition, FMDV C-S8cl and
MAb-resistant variants of FMDV C-S8c1 were also serially
passaged in the absence of antiviral antibodies (15 series)
(Fig. 1). FMDV populations BiplO, Blp2O, B2plO, B2p20,
Clp2O, C2plO, C2p20, Dlp2O, D2p20, HiplO, Hlp2O,
H2plO, and H2p20 or clonal populations derived fromAlp2O
(cl to c9) produced normal virus yields. In contrast, popu-
lations A1, A2, CiplO, DiplO, and D2piO produced titers 1
or several orders of magnitude below normal (Table 1).
Furthermore, dilutions below those required to titrate pop-
ulation Aip2O, A2p20, or DlplO caused deterioration of the
BHK-21 cell monolayers, an observation suggestive of abor-
tive infections by defective particles. FMDV Al and A2
maintained their low-yield phenotype up to passage 20
J. VIROL.
ANTIGENIC VARIANTS OF FMDV 6073
NO ANTI-FMDV ANTIBODIES
C-Sta Pau Sp /70
.
Q) FMDV G-S8cl
iAN
'4If--
4TI - A24 ANTIBODIES
00. 00
15 SERIES
* * *
411 441
0 0 ................
2
*o o
14 15
*
0.
*
00 00 00 00 00 -Pi
1 1 1 1 1 1 f 1
: : : : : : : :
* * * . * . *
* * * . * * *
* . * * * * *
: : : : : : : :
* * * * * . * .
ll
*
*
*
*
*
*
* -
* 7
Ial |a2 4bl 4b2 4cl 4c2 4dl 4d2 |hl 4h2
00 00 00 00 00
Al A2 Bl B2 Cl C2 Dl D2 Hi H2
? 00
* v
-.] p20
-] p10
f p100
FIG. 1. Scheme of passages of FMDV C-S8c1 in BHK-21 cells with and without anti-FMDV antibodies. FMDV C-S8c1 is a three-times
plaque-purified derivative (filled squares) of isolate C-Sta Pau Sp/70 (45). The same initial preparation was serially passaged in the absence
(series 1 to 15 and hl and h2, empty circles) or presence (series a to d, circles with diagonal lines) of anti-peptide A24 antibodies; h is a serum
from a guinea pig inoculated with herpes simplex virus. Results for antigenic variation of FMDV C-S8c1 of most passage series 1 to 15 have
been previously described (11, 12, 31); other series will be described elsewhere (25). Procedures to prepare peptide A24 and anti-A24 sera and
to passage virus are indicated in Materials and Methods. The passage number is written on the right; populations Alp2O and A2p20 were
further passaged 10 times in the absence of antiviral antibodies to yield populations plO-1 and p10-2 (duplicate series; see text). Some of the
15 series passaged with no antiviral antibodies were passaged 100 times (25).
whereas FMDV Cl, D1, and D2 produced low yields at
passage 10 but normal or nearly normal yields by passage 20.
FMDV Alp2O and A2p20 regained totally or partially the
ability to produce viral progeny when they were further
passaged without antipeptide serum (Table 1). FMDV titers
were an inheritable trait of each population and were not
influenced by residual antibodies present in the assays
(Table 1). We considered the possibility that, irrespective of
the selection constraint exerted by antibodies, FMDV could
show a decrease in fitness by the gradual accumulation of
deleterious mutations anywhere in the genome due to re-
peated population bottlenecking (8, 9, 20) caused by the
reduction in viral titer upon treatment of FMDV with anti-
bodies (see Materials and Methods). To test this possibility,
we subjected sextuplicate samples ofFMDV C-S8cl to serial
passage, introducing between each passage a 103-fold titer
reduction so as to mimic the bottleneck effect experienced
by populationsA and B. None of the six lineages showed any
decrease in virus titer, which was in the range of 7 x 107 to
4 x 108 PFU/ml (compare with values in Table 1). Interest-
ingly, nine clones derived by isolating virus from nine
individual plaques obtained by plating population Alp2O
produced normal yields (Table 1), suggesting that a quasi-
species of highly debilitated genomes interfered or sup-
pressed high-fitness variants included in the quasispecies
(10).
The neutralization titers of each of the polyclonal guinea
pig sera (a, b, c, and d) were quantitated with the parental
FMDV C-S8cl, its MAb-resistant (MAR) mutant H-146-+R
(36, 37), and the passaged C-S8cl populations. The results
shown in Table 2 indicate selection of antigenic variants in
each of the populations propagated in the presence of
anti-peptide A24 sera. This is particularly clear for the
populations at passage 20 which showed a decrease in
neutralization of at least a factor of 10. As expected, no
resistance to neutralization was noted in FMDV treated and
passaged with serum h, nor did serum h neutralize to any
significant extent any of the viral populations tested (Table
2). However, some of the anti-peptide A24 sera tested
showed a deviant behavior when confronted with different
FMDV populations. For example, serum b neutralized to the
same extent C-S8cl and MAR mutant H-146- R, whereas
sera a, c, and d were significantly more effective in neutral-
izing C-S8cl than its MAR mutant derivative. In some cases,
duplicate passage series led to virus populations with a
different degree of resistance against the same serum; for
example, Dlp2O was neutralized more efficiently than D2p20
by its homologous serum d; also, Blp2O and B2p20 were
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TABLE 1. Decreased yield of some viral populations derived
from FMDV C-S8cl under selection by antibodies
directed to antigenic site A'
FMDV Titer (PFU/ml)
C-S8cl, series 1 to 15, B, C2, H,
Alp2O, cl to c9 ........................ 1 x 107-1 X 108
AlplO ........................ 3 x 103
Alp2O ........................ 3 x 102
Alp2O,pl-1 .........................1 x 102
Alp2O,plO-1 ........................ 2 x 105
Alp2O,pl-2 ........................ 2 x 102
Alp2O,plO-2 ........................ 4 x 106
A2plO ........................ 1 x 104
A2p20 ........................ 6 x 103
A2p20,pl-1 ........................ 4 x 104
A2p20,plO-l........................1 x 107
A2p20,pl-2 ........................ 2 x 104
A2p20,plO-2 ........................ 4 x 106
ClplO......................... 4 x 105
Clp2O ........................ 1 x 107
DlplO........................ 2 x 104
Dlp2O ........................ 7 x 106
D2plO ........................ 7 x 104
D2p20 ........................ 7 x 106
a The origin of the FMDV populations analyzed is depicted in Fig. 1. Titers
were determined by triplicate plating of the appropriate dilutions, as previ-
ously described (45). Titers produced by FMDV C-S8cl (and several addi-
tional populations tested) did not vary significantly in a range of multiplicities
of 0.0001 to 10 PFU per cell. The residual antibodies present in the popula-
tions tested did not affect the viral yield, as shown by the titers obtained with
populations passaged once in the absence of antibodies (populations indicated
as pl-1 or pl-2) before the analysis of viral yield. The same control was
applied to populationsAlp5,Alp9, A2p5, andA2p9 with identical conclusions
(data not shown). Alp2O, cl to c9, are nine plaque-purified clones derived
from population Alp20. The values given are the averages of at least two
determinations; values deviated less than 20% from the mean.
neutralized to a similar extent by homologous serum b, but
Blp2O was more resistant than B2p20 to neutralization by
any heterologous serum (Table 2).
Populations Alp2O and A2p20 could not be subjected to
reliable neutralization measurements because of their poor
plaquing efficiency (Table 1). For this reason, several plaque
isolates were derived from populationAlp20 (by plating high
viral dilutions on large BHK-21 cell monolayers) and tested
for neutralization against homologous serum a. The results
(Table 2) show clonal heterogeneity in resistance to neutral-
ization: c3 and c8 manifested high resistance to serum a
while c4 and c7 were only slightly more resistant than
C-S8cl. Populations derived from Alp2O or A2p20 by pas-
sage in the absence of anti-peptide A24 antibodies (popula-
tions Alp2O,plO-1; Alp2O,plO-2; A2p20,plO-l; and A2p20,
p10-2) showed only limited resistance to neutralization by
serum a, comparable to that of clones c4 and c7 isolated
from population Alp2O (Table 2). As documented below,
resistance to neutralization by polyclonal sera of uncloned
populations or of individual FMDV clones correlated with
amino acid replacements at H-146 of capsid protein VP1.
Altered reactivity with MAbs. Since peptide A24 repre-
sents the amino acid sequence of antigenic site A of FMDV
C-S8cl, it was possible that viral populations selected as
resistant to sera a, b, c, and d were also resistant to
neutralizing MAbs specifically directed to site A (36, 37).
The results with six viral populations (Table 3) show three
distinct patterns of neutralization by a panel of six MAbs
which recognize different epitopes located within antigenic
site A (36, 37). Populations A2p20,plO-2; B1plO; and D2p20
lost most site A epitopes present in C-S8cl, similar to MAR
TABLE 2. Neutralization titers for polyclonal sera with FMDV
clones and passaged populations
Titer for serumb:
FMDVa
a b c d h
C-S8cl 3.4 3.6 4.7 4.8 <1.0
MAR H-146--R 2.6 3.8 3.4 3.6 <1.0
AlplO 2.9 ND ND ND ND
Alp2O,c3 1.5 ND ND ND ND
Alp2O,c4 3.0 ND ND ND ND
Alp2O,c7 2.8 ND ND ND ND
Alp2O,c8 1.5 ND ND ND ND
Alp2O,plO-1 2.7 3.4 4.3 4.4 < 1.0
Alp2O,plO-2 3.3 3.5 4.5 4.6 < 1.0
A2plO 2.8 ND ND ND ND
A2p20,plO-1 2.5 3.9 3.1 3.4 <1.0
A2p20,plO-2 2.6 3.6 2.8 3.3 < 1.0
BlplO 1.2 1.2 2.5 2.4 < 1.0
Blp2O 1.0 1.0 2.4 2.4 < 1.0
B2plO 3.2 1.0 3.8 3.7 < 1.0
B2p20 2.5 1.4 3.1 3.7 < 1.0
ClplO 3.4 3.7 4.3 4.4 <1.0
Clp2O 1.2 1.0 2.3 2.4 <1.0
C2plO 1.9 3.5 2.5 2.7 <1.0
C2p20 <1.0 <1.0 2.4 2.8 <1.0
Dlp2O < 1.0 1.0 1.9 2.3 <1.0
D2plO 3.4 3.8 5.0 4.9 <1.0
D2p20 < 1.0 < 1.0 1.7 1.2 <1.0
HlplO 3.3 3.0 4.7 4.7 < 1.0
Hlp2O 3.3 3.4 4.4 4.5 < 1.0
H2plO 3.5 3.0 4.1 4.4 <1.0
H2p20 3.3 3.4 4.4 4.6 < 1.0
a The passage history of each FMDV population analyzed is depicted in
Fig. 1. MAR H-146-R is a mutant of C-S8c1 initially selected by its resistance
to MAb SD6, specific for antigenic site A (36, 37); c3, c4, c7, and c8 are four
plaque-purified clones derived from population Alp2O.
b Serum neutralization titers are expressed as the logarithm of the recipro-
cal of the serum dilution which caused a neutralization of 70% of PFU (38).
Each value is the result of at least two neutralization curves in which each of
four titrations-corresponding to four antibody dilutions-was carried out in
duplicate. Standard deviations (a total of at least four platings for each
antibody dilution) were below 15%. ND, not determined. Procedures for the
preparation of guinea pig sera and for plaque assays are described in Materials
and Methods.
mutant H-146---R (36). In contrast, B2plO and B2p20 main-
tained the epitopes defined by MAbs SD6, 6D11, and 4F1
(Table 3). Population H2plO was neutralized by all MAbs
tested except 4G3. Increased resistance to 4G3 or SD6 was
also observed in some populations of series 1 to 15 (Fig. 1)
passaged in the absence of anti-FMDV antibodies (12, 25).
Thus, FMDV populations selected in the presence of anti-
peptide A24 antibodies showed alterations at several
epitopes located within antigenic site A of FMDV C-S8cl.
Amino acid replacements at a specific site A position in the
presence of immune selection. To interpret the different
extents of neutralization of the passaged FMDVs by poly-
clonal sera (Table 2) and by MAbs (Table 3), the VP1-
encoding region of each population at passages 10 and 20
was sequenced (Fig. 2). Several amino acid substitutions
within antigenic site A, and also elsewhere in VP1, occurred
in each passaged population. Remarkably, each of the vi-
ruses treated and propagated with anti-peptide A24 antibod-
ies, and that reached high levels of resistance by passage 20,
included a replacement of the histidine at position 146
(H--R, H--Q, or H- Y) (Fig. 2). Resistance to neutraliza-
tion by most MAbs directed to site A (Table 3) was associ-
ated with either replacement H-146--Q or H-146-*R, in
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TABLE 3. Neutralization titers for MAbs with FMDV clones and
passaged populationsa
Titer for MAb:
FMDV
SD6 6D11 4F1 4G3 7JD1 7FC12
C-S8cl 2.4 3.4 3.5 2.4 2.8 2.4
MAR H-146--+R <1.0 1.7 <1.0 <1.0 <1.0 <1.0
A2p20,plO-2 <1.0 2.8 <1.0 <1.0 <1.0 <1.0
BlplO < 1.0 1.4 < 1.0 < 1.0 < 1.0 <1.0
B2plO 2.2 3.5 3.5 1.2 < 1.0 <1.0
B2p20 1.8 3.8 3.3 < 1.0 ND ND
D2p20 < 1.0 1.3 < 1.0 <1.0 < 1.0 <1.0
H2plO 2.5 4.1 3.5 < 1.0 3.2 3.3
a The MAbs used recognize different epitopes within antigenic site A and
have been previously described (36, 37). The VP1 positions which when
substituted affected the reactivity with the MAbs used were as follows: SD6,
6D11, and 4F1, 138, 139, and 146; 4G3, 146, 148, 149, and 150; and 7JD1 and
7FC12, 146. Since antigenic site A appears as flexible and disordered on the
capsid surface (1), it is not possible at present to assign the epitopes
recognized by the MAbs used to any defined protein structure. Neutralization
titers are expressed as the logarithm of the reciprocal of the dilution of the
supernatant of a hybridoma culture (MAbs SD6, 4F1, 7JD1, and 7FC12) or
ascitic fluid (MAbs 6D11 and 4G3) which caused neutralization of 70% ofPFU
(38). Standard deviations (calculated as indicated in Table 2, footnote b), were
below 10%. ND, not determined. The preparation of MAbs has been previ-
ously described (38). Procedures for plaque assays and the origin of the
FMDVs analyzed are described in Materials and Methods and in Table 2,
footnote a.
agreement with previous observations with natural isolates
and several MAR mutants that showed that these two
replacements at H-146 abolished most or all of the epitopes
identified within site A of FMDV C-S8cl (6, 33, 36). In
contrast, the reactivity of FMDV B2plO and B2p20 with
MAbs suggests that replacement H-146--Y-alone or in
combination with replacement T-149--K-had a less drastic
effect on antigenic specificity than H-146--Q or H-146--+R
(Fig. 2 and Table 3). Comparison of neutralization of B2plO
and B2p20-two viruses with an average VP1 amino acid
sequence showing substitutions only within antigenic site A
(Fig. 2)-suggests an enhanced resistance to neutralization
by sera a and c (but not by homologous serum b) as a
consequence of replacement T-148- A in the context of
amino acids Y-146 and K-149 (compare Fig. 2 and Table 2).
However, it cannot be completely excluded that substitu-
tions elsewhere in the capsid could exert some distance
effect on neutralization by antibodies (see Discussion). An
indetermination is also encountered in trying to interpret the
low viral yields produced by several populations subjected
to immune selection (Table 1) (see below and Discussion).
The complexity of the viral populations under study
became obvious when the RNA encoding the region around
site A of 15 plaque-purified derivatives of populations
AiplO, A2plO, and Alp2O was sequenced (Fig. 3). At least
five different sequences with combinations of replacements
at positions 146 and 167 were present. Comparison of
neutralization titers (Table 2) and amino acid sequences (Fig.
3) of four FMDV clones derived from population Alp2O
reinforces again the association of replacement H-146- R
with resistance to neutralization by serum a. Also, in spite of
the suggestion from the data in Fig. 2 and Table 1 that
substitution E-167--K could be associated with low viral
yields, the high yields produced by each clone derived from
Alp2O-irrespective of including K, E, or Q in position 167
(Fig. 3)-suggest that the low viral yields of the uncloned
parental population Alp2O cannot be attributed solely to
substitution E-167--K. These observations emphasize once
more the importance of carrying out clonal analyses before
attempting to ascribe defined genetic lesions to the behavior
of a complex quasispecies.
Nonidentical set of amino acid replacements in the presence
or the absence of immune selection. The comparison of amino
acid substitutions that occurred at antigenic site A upon
passage of FMDV C-S8cl in the presence or absence of a
specific immune selection shows two distinct but overlap-
ping sets of amino acids (Fig. 4) under the two passage
conditions. Substitutions T-148-*S, H-146--*R, H-146--*Q,
and H-146- Y occurred only when FMDV was passaged
under strong selection by antibodies. In particular, a substi-
tution at position 146-previously associated with a drastic
change in antigenic specificity (33, 36)-was found in none of
the 17 passage series carried out in the absence of anti-
FMDV antibodies but in each of 8 series under specific
antibody selection. This is a strong bias which cannot be the
result of chance (see Discussion).
We conclude that antigenic diversification of FMDV can
occur upon passage of the virus in the presence or absence of
selecting antibodies, but that the amino acid substitutions
fixed under conditions of strong positive selection are not
identical to those fixed in the absence of immune selection.
Replacement of the antigenically critical H-146 residue of
VP1 occurred repeatedly when FMDV was subjected to
selection by antibodies, but it was never observed upon
virus propagation in the absence of immune selection. Vi-
ruses selected by polyclonal antibodies may manifest
marked loss of fitness which may be rapidly recovered upon
virus propagation in the absence of selecting antibodies.
Such a fitness recovery did not necessarily involve reversion
of the antigenically relevant amino acid substitutions; for
example, populations A2p20,plO-1 and A2p20,plO-2 re-
gained the ability to produce normal or nearly normal yields
(Table 1) and both maintained the critical replacement
H-146--Q (Fig. 2). Low-fitness quasispecies populations
selected by neutralizing antibodies are genetically and anti-
genically complex and include high-fitness variants with
distinguishable antigenic specificities.
DISCUSSION
In the stretch of 24 amino acids in which a total of four
positions were changed upon serial passage of FMDV
C-S8cl (Fig. 4), the probability that one particular position
(in this case H-146) would be substituted by chance in each
of the eight passage series in the presence of anti-peptide
A24 antibodies is negligible. [The probability of such an
occurrence is given by the binomial distribution as (2.37/24)8
= 0.0988 = 8.5 x 10-, in which 2.37 is the average number
of positions which varied per passage series, 24 is the
number of amino acids in the sequence considered, and 8 is
the number of passage series]. Substitution T-148-3S was
also found only under immune selection in populations
derived from A2p2O (Fig. 2), but its statistical significance
cannot be established with the number of parallel passage
series involved. Our results suggest that the types of unse-
lected replacements commonly found within antigenic site A
(11, 12, 31) alter the antigenicity to an extent which is
insufficient to permit a successful evasion of the virus from a
polyclonal response even if the latter was directed specifi-
cally to site A. Immune selection may force low-fitness, rare
variants from the mutant spectrum-harboring appropriate
amino acid substitutions-to become dominant. In contrast,
fluctuations in the viral quasispecies in the absence of
anti-FMDV antibodies may often allow dominance of vari-
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FIG. 2. Amino acid sequence of VP1 of FMDV C-S8cl (46, 50) and of populations passaged in the presence of serum a, b, c, d, or h. The
single-letter amino acid code is used. On the amino acid sequence of VP1 of FMDV C-S8cl (top), secondary-structure motifs are indicated,
assuming that, upon alignment, they correspond to the equivalent residues of FMDV 01 BFS 1860 (1). The box corresponds to the sequence
of peptide A24 used to prepare sera a, b, c, and d, as described in Materials and Methods. Amino acid differences in the passaged populations
relative to C-S8cl are indicated below the sequence. Each amino acid substitution resulted from a single transition or transversion mutation.
Two amino acids separated by a shill at a given position indicate a mixture of two nucleotides at the corresponding position. The stretch
spanning positions 140 to 167 has been expanded. Each of the sites in which substitutions occurred corresponds to an exposed region of the
FMDV capsid (1). In addition to the amino acid substitutions given, the following silent replacements were found (viral populations in
parentheses): T-45-C (A2p2O; A2p20,plO-1; A2p20,plO-2); A-231->G (A2p2O; A2p20,p10-1; A2p20,plO-2); G-384--*G/T (H2p20); T-417--*C
(A2p2O; A2p20,p10-1; A2p20,plO-2); C-525--T/C (Alp20,plO-2); A-540- G (C2p20) (numbering of nucleotides corresponds to the numbering
of the encoded amino acids shown at the top). The passage history of the populations analyzed is shown in Fig. 1, and the neutralization titer
with polyclonal sera and MAbs is shown in Tables 2 and 3, respectively.
ants with more neutral replacements capable of altering one
but not many epitopes at important antigenic sites. The
drastic nature of the alterations in antigenic specificity
mediated by replacements selected with antibodies is clearly
documented by modifications in neutralization titer of MAbs
and of polyclonal sera (Table 2).
The results of passage of FMDV C-S8cl in the presence of
anti-peptide A24 antibodies suggest that sera raised in dif-
ferent animals may exert different selective pressures result-
ing in different mutations in VP1 and different effects on viral
fitness (Table 1); the biochemical basis of such a fitness
decrease has not been established. A more subtle fitness
decrease-noticeable only in growth competition experi-
ments with a reference FMDV-was previously documented
for MAR mutant H-146--3R (31). In most populations se-
lected by anti-peptide A24 antibodies, a fitness gain was
observed by passage 20 in spite of the continuing presence of
anti-FMDV antibodies, suggesting a rapid adjustment of the
viral population to the environmental change. However, the
strong reduction of fitness in viruses passaged in the pres-
ence of serum a could be overcome only by passaging the
virus in the absence of antibodies (Table 1). These observa-
tions suggest that the capsid of FMDV may be subjected to
very severe constraints for variation and that only a small
number of capsid residues tolerate replacements by very few
amino acids, as previously documented for long-term evolu-
tion of FMDV type C in the field (32). Thus, it may be
possible to induce an immune response-even by a single
chemically defined peptide-of a nature such that chances of
producing escape viruses with high fitness seem limited. Of
course, a single, defined, conjugated peptide may acquire
multiple conformations, some of which may fortuitously
mimic capsid stretches other than antigenic site A, thus
inducing a broader immune response than expected from its
sequence. We are currently analyzing serum a, and addi-
tional mutants selected by it, in an attempt to understand its
ability to suppress FMDV viability.
Most of the amino acid substitutions detected in VP1 (Fig.
2) occurred at exposed surface residues close to the viral
fivefold axis (K-41--*E in OB, T-83---A and K-85-->T in loop
209
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K
K
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ANTIGENIC VARIANTS OF FMDV 6077
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FIG. 3. Complexity of the site A quasispecies in populations
AlplO,A2plO, andAlp20. The RNA stretch corresponding to amino
acids 103 to 168 of VP1 was sequenced for a total of 15 biological
clones (3 clones each from populations AlplO and A2p10 and 9
clones fromAlp20). The amino acid sequence of VP1 is given in Fig.
2. Only the amino acids which differ from those in C-S8cl are
written. The four boxed viral populations are those subjected to the
neutralization assay with serum a (compare with Table 2). Three
clones showed sequence heterogeneity in the bands of sequencing
gels at the indicated residues. These mixed populations were not
further analyzed. Arrows indicate five different sequences based on
variations at residues 146 and 167. The origin of the viral populations
analyzed is shown in Fig. 1.
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FIG. 4. Amino acid replacements within antigenic site A of
FMDV C-S8cl upon passage of the virus in the absence (substitu-
tions indicated above VP1 residues 133 to 156 of C-S8cl) or in the
presence (indicated below the C-S8cl sequence) of anti-peptide A24
antibodies. Only amino acid replacements are indicated. Substitu-
tions in the absence of anti-FMDV antibodies occurred under the
following passage conditions in BHK-21 cells: S-139--*R, T-148--K,
and T-150->K were obtained after 30 passages of FMDV C-S8cl at
a multiplicity of infection of 0.1 to 0.2 PFU per cell (12); T-148-->K
was also fixed during a persistent infection of FMDV C-S8cl in
carrier BHK-21 cells (11); T-133--A, A-140->V, T-148->A,
T-148->K, T-149---A, T-149-->K, and H-154->R were observed upon
30 to 100 passages of FMDV C-S8cl or of MAR mutants of FMDV
C-S8cl at a multiplicity of infection of 2 to 4 PFU per cell (25, 31);
in addition, T-148--K and T-150-->K were also seen in the passage
series in the presence of serum h (compare with Fig. 2). Encircled
residues are those found in both the absence and the presence of
immune selection. The highly conserved RGD sequence is under-
lined. Note the H-146 repeatedly substituted only in populations
subjected to antibody selection.
D-E, V-95--3F in loop E-F, H-108-->R in ,BF, and E-167-->K in
loop H-I; see reference 1 and Fig. 2), and as such it is not
obvious how they could either affect neutralization by anti-
bodies directed to site A or influence viral fitness. However,
positions in the B-C loop of FMDV 01 BFS 1860 close to the
fivefold axis affected binding of MAbs which recognize site
A (40, 41), and we cannot exclude that replacements at a
distance from antigenic site A may modulate neutralization
by antibodies or viral fitness by unknown mechanisms. Most
populations selected with polyclonal sera show a signifi-
cantly higher resistance to neutralization by polyclonal sera
than MAR mutant H-146--+R (Table 2). Since that mutant
includes H-146---R as the only replacement in its entire
capsid (24), it is clear that additional replacements in the
capsid of the selected FMDV populations must contribute to
the observed level of resistance to neutralization. Prelimi-
nary results of sequencing capsid proteins VP2 and VP3
have evidenced amino acid replacements at multiple sites
even in viruses propagated in the absence of anti-FMDV
antibodies (25). Thus, it may be often difficult, even after
extensive sequencing, to assign amino acid replacements
precisely to a pattern of reactivity with antibodies. An
additional complication is the extreme complexity of the
FMDV quasispecies evolving under immune selection (Fig.
3). It may be significant that none of the five different
sequence patterns-considering positions 146 and 167 of
VP1-found in the AlplO, A2plO, or Alp2O quasispecies
(arrows in Fig. 3) is represented in any natural FMDV isolate
of serotype C sequenced to date (32, 33). One interesting
possibility is that the complexity of the quasispecies during
immune selection may result from FMDV being far from
population equilibrium (15) and from the fact that multiple
amino acid substitutions, even at exposed capsid sites, may
deviate FMDV from optimal fitness. In this respect, it is
noteworthy that the quasispecies Alp2O includes variants
with the same amino acid as C-S8c1 in position 146 or 167
(Fig. 3).
Replacement H-146--3Y in VP1 of FMDV had not been
described previously in any FMDV mutant, and H-146--*R
was found previously only among MAR mutants of FMDV
C-S8cl (36, 37). In contrast, H-146--*Q appears to have
occurred occasionally during the natural evolution ofFMDV
type C since Q-146 was present in a few isolates from
Argentina and the Philippines, most other lineages and likely
ancestors having H at this position (33). Also, Q-146 was
present in viruses isolated from carrier cattle in which a
persistent infection was established experimentally with
FMDV C3 (23). There is considerable evidence that substi-
tution H-146--+Q has contributed to the modification of
antigenic specificity of FMDV type C (33, 35). In our passage
series, this replacement became dominant exclusively under
immune selection (Fig. 4).
Our results caution against attributing the preferential
fixation of amino acid substitutions within antigenic sites of
rapidly evolving RNA viruses to Darwinian selection. Only
after appropriate sequence comparisons of populations se-
lected by antibodies and those evolved without immune
pressure may it be possible to distinguish between positive
selection and acceptance of mutations at sites where they are
most tolerated (13, 14, 16). Finally, our observations have
implications for the general molecular evolution of proteins.
Indeed, concerning the neutralist-selectionist controversy
(13, 22, 29, 49), the possibility that an altered phenotype may
be attained both by random drift of neutral or nearly neutral
alleles and by positive Darwinian selection must be consid-
ered. In our studies, the association of the replacement at
VP1 position 146 with a large antigenic change and with
108
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positive selection events could only be established because
multiple virus variants and well-characterized reagents
(polyclonal sera and MAbs) were available to express phe-
notypic alterations in a quantitative fashion. In the evolution
of cellular proteins, a dual evolution by random events or by
positive selection could also potentially occur, as could
functional adaptations attained by one or the other mecha-
nism.
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